June 2026
Create an account to continue using Similarweb
View website metrics, keywords, top marketing channels, market research tools, and more.
Create your free accountatypicalhus.50megs.com
Global Rank
- -
Country Rank
- -
Category Rank
- -
Showing Similarweb estimated data.
Publicly validate your site’s metrics by connecting your GA4
Reflect your success
Verify your website's traffic and engagement metrics by connecting to Google Analytics
Bounce Rate
- -
Pages per Visit
- -
Avg Visit Duration
- -
- Company
- - -
- Industry
- - -
Top 10 atypicalhus.50megs.com Competitors
The Top 10 Sites Like atypicalhus.50megs.com in June 2026 are ranked by their affinity to atypicalhus.50megs.com in terms of keyword traffic, audience targeting, and market overlap
KCA is a global community dedicated to serving and empowering patients and caregivers, and leading change through advocacy, research, and education.
- Company
- - -
- Industry
- - -
Global Rank
#1,120,763
350,007Bounce Rate
50.86%
Pages per Visit
1.67
Avg Visit Duration
00:00:23
Similarity Score
100%important safety information warning: embryo-fetal toxicity and venous thromboembolism embryo-fetal toxicity if thalidomide is taken during pregnancy, it can cause severe birth defects or embryo-fetal death. thalidomide should never be used by females who are pregnant or who could become pregnant while taking the drug. even a single dose [1 capsule (regardless of strength)] taken by a pregnant woman during her pregnancy can cause severe birth defects because of this toxicity and in an effort to make the chance of embryo-fetal exposure to thalomid® (thalidomide) as negligible as possible, thalomid® (thalidomide) is approved for marketing only through a special restricted distribution program: thalomid rems® program, approved by the food and drug administration you can get the information about thalomid and the thalomid rems® program on the internet at www.celgeneriskmanagement.com or by calling the manufacturer's toll-free number 1-888-423-5436 venous thromboembolism the use of thalomid (thalidomide) in multiple myeloma results in an increased risk of venous thromboembolism, such as deep venous thrombosis and pulmonary embolism. this risk increases significantly when thalidomide is used in combination with standard chemotherapeutic agents including dexamethasone. in one controlled trial, the rate of venous thromboembolism was 22.5% in patients receiving thalidomide in combination with dexamethasone compared to 4.9% in patients receiving dexamethasone alone (p = 0.002). patients and physicians are advised to be observant for the signs and symptoms of thromboembolism. instruct patients to seek medical care if they develop symptoms such as shortness of breath, chest pain, or arm or leg swelling. consider thromboprophylaxis based on an assessment of individual patients’ underlying risk factors contraindications pregnancy: see boxed warnings. thalomid can cause fetal harm when administered to a pregnant female. thalomid is contraindicated in females who are pregnant. thal
- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
- -
Pages per Visit
- -
Avg Visit Duration
- -
Similarity Score
64%Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.
- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
- -
Pages per Visit
- -
Avg Visit Duration
- -
Similarity Score
64%Find HUMIRA full prescribing information including Important Safety Information and the BOXED WARNING.
- Company
- - -
- Industry
- - -
Global Rank
#2,802,097
216,701Bounce Rate
45.1%
Pages per Visit
1.56
Avg Visit Duration
00:00:11
Similarity Score
63%the official healthcare professional website for pentasa® (mesalamine). read safety info including use in patients with hepatic impairment.
- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
- -
Pages per Visit
- -
Avg Visit Duration
- -
Similarity Score
63%US WorldMeds is a specialty pharmaceutical company that develops, licenses, and brings to market unique healthcare products designed to improve lives.
- Company
- US WorldMeds
Global Rank
#4,009,739
7,142,130Bounce Rate
34.47%
Pages per Visit
1.95
Avg Visit Duration
00:01:14
Similarity Score
62%Breakthrough science. One moment, one day, one person at a time.
- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
- -
Pages per Visit
- -
Avg Visit Duration
- -
Similarity Score
62%enter a brief description of your site here
- Company
- - -
- Industry
- - -
Global Rank
#11,846,142
Bounce Rate
41.58%
Pages per Visit
1.11
Avg Visit Duration
- -
Similarity Score
62%find sanofi us corporate information, pharmaceutical products, news, career opportunities and health resources.
- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
76.84%
Pages per Visit
2.27
Avg Visit Duration
00:01:01
Similarity Score
62%Complete the form below and a Median representative will follow up with you to set up time to discuss your needs and how Median Technologies can support you.
Global Rank
#2,516,975
31,723Bounce Rate
44.78%
Pages per Visit
1.73
Avg Visit Duration
00:00:33
Similarity Score
62%atypicalhus.50megs.com's top 5 competitors in June 2026 are: kidneycancer.org, thalomid.com, sensipar.com, humirapro.com, and more.
According to Similarweb data of monthly visits, atypicalhus.50megs.com’s top competitor in June 2026 is kidneycancer.org. atypicalhus.50megs.com 2nd most similar site is thalomid.com, and closing off the top 3 is sensipar.com.
humirapro.com ranks as the 4th most similar website to atypicalhus.50megs.com and pentasaus.com ranks fifth in June 2026.
The other five competitors in the top 10 list are usworldmeds.com, fuzeon.com, drunderberg.com, products.sanofi.us, and mediantechnologies.com.